- News
- Announcements
Announcements
Current & archive
Transparency: Sponsoring of patient initiatives, Update
As patient organisations continue to professionalise and expand their activities, their need for financial resources is also increasing, which is often covered by pharmaceutical companies. In order to make these financial flows more transparent, the pharmaceutical industry has responded with voluntary commitments to greater transparency. The AIHTA (then still known as LBI-HTA) systematically analysed this data on sponsorship of patient initiatives for the first time in 2014 and aims to carry out consistent and ongoing monitoring of payments. The present fourth update of the systematic analysis investigated the extent to which patient initiatives in Austria were financially supported by pharmaceutical companies in 2019.
In 2019, only 39 out of a total of 115 PHARMIG member companies disclosed financial contributions to patient initiatives. Compared to 2018, the disclosure rate dropped from 43 to 34 per cent, while at the same time there was a significant increase in the amount of money declared by 37 per cent to around 2.3 million euros. In 2019, the areas of haemato-oncology (around 16 per cent of the total) and haemophilia (around 13 per cent) received the largest share, followed by lung diseases, diabetes and metabolic diseases.
Publication: Policy Brief No. 007: https://eprints.aihta.at/1308
Contact: Ozren Sehic
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our four new HSO Fact Sheets.
Fact Sheet No. 47 (April 2021)
Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)
Fact Sheet No. 48 (April 2021)
Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)
Fact Sheet No. 49 (April 2021)
Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 50 (April 2021)
Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma
Covid-19: HSS/ Horizon Scanning Living Document (v14 May 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 44 (March 2021)
Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)
Fact Sheet No. 45 (March 2021)
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 46 (March 2021)
Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
Covid-19: HSS/ Horizon Scanning Living Document (v13 April 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence – recommendations from evidence-based guidelines
Several previous reports researched and summarised screening recommendations from evidence-based guidelines for pregnant women and children. The aim of this update was to review the guideline recommendations for mental health, nutrition, and social competence from previous reports to ensure they were current and to provide an update. The total of 52 included guidelines recommend screening and/or counselling for the majority of the topics addressed. The update report can subsequently be used as a decision support for an updated screening program for pregnant women and children.
Publication: Policy Brief Nr. 005: http://eprints.aihta.at/1303/
Contact: Inanna Reinsperger
Robotics and functional electrical stimulation for stroke rehabilitation
Robotic assisted rehabilitation (RAR) and functional electrostimulation (FES) can, among others, be used as a supplement to conventional rehabili-tation in post-stroke patients. The use of RAR could have the advantage of allowing more intensive and frequent therapy (by increasing the motiva-tion to train), which at the same time reduces the effort of the physiotherapist. FES is a targeted application of electrical stimulation inducing muscle contractions supporting motor activities. The electrical stimulation takes place during a functional movement and may, inter alia, strengthen the muscle and improve blood circulation or blood flow.
This report aimed at evaluating the additional clinical benefit of RAR and FES. Systematic reviews of effectiveness and safety were conducted in cooperation with a working group (ReMoS/ Rehabilitation of Mobility after Stroke - AG) of the Association of the Scientific Medical Societies in Germany (AWMF)
Publication: LBI-HTA Project Report No.: 128: https://eprints.aihta.at/1302
Contact: Gregor Goetz
Horizon Scanning in Oncology - Fact Sheets
Fact Sheet No. 41 (February 2021)
Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)
Fact Sheet No. 42 (February 2021)
Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
Fact Sheet No. 43 (February 2021)
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)
Covid-19: HSS/ Horizon Scanning Living Document (v12 March 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 38 (January 2021)
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)
Fact Sheet No. 39 (January 2021)
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 40 (January2021)
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
